PTGER4, prostaglandin E receptor 4, 5734

N. diseases: 120; N. variants: 3
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0021368
Disease: Inflammation
Inflammation 		0.500 Biomarker phenotype CTD_human MF498 [N-{[4-(5,9-Diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-(2-methoxyphenyl)acetamide], a selective E prostanoid receptor 4 antagonist, relieves joint inflammation and pain in rodent models of rheumatoid and osteoarthritis. 18287210 2008
CUI: C0021368
Disease: Inflammation
Inflammation 		0.500 Therapeutic phenotype RGD This is the first study to confirm the in-vivo effects of EP4 receptor blockade on inflammation and bone destruction in AIA rats with a small-molecule compound. 18498708 2008
CUI: C0038013
Disease: Ankylosing spondylitis
Ankylosing spondylitis 		0.330 GeneticVariation disease BEFREE Interestingly, recent genome-wide association studies (GWAS) have identified five risk alleles for AS in PTGER4, the gene encoding for EP4. 31253169 2019
CUI: C0014175
Disease: Endometriosis
Endometriosis 		0.330 Biomarker disease BEFREE In the endometriotic lesions, prostaglandin E2 (PGE2) produced by cyclooxygenase-2 (COX-2), binds to its EP4 receptor (EP4), and via c-Src kinase induces MMPs activation, promoting endometriosis. 27038655 2016
CUI: C0014175
Disease: Endometriosis
Endometriosis 		0.330 AlteredExpression disease BEFREE Prostaglandin-endoperoxidase synthase (PTGS)1, PTGS2, prostaglandin E receptor (PTGER)1, PTGER2, PTGER3, and PTGER4 mRNA levels in endometrium of disease-free women and in eutopic and ectopic endometrium of endometriosis-affected women. 24423291 2014
CUI: C0014175
Disease: Endometriosis
Endometriosis 		0.330 Biomarker disease BEFREE The level of annexin A2 mRNA in the macrophages was reduced by PGE2 (P < 0.01/P < 0.05 in women without/with endometriosis versus control) via the EP2/EP4 receptor-dependent signaling pathway. 23340055 2013
CUI: C0038013
Disease: Ankylosing spondylitis
Ankylosing spondylitis 		0.330 GeneticVariation disease BEFREE We aim to examine the influence of JARID1A, JMY, and PTGER4 polymorphisms on the susceptibility to and the severity of ankylosing spondylitis in Chinese ethnic majority Han population. 24069348 2013
CUI: C0038013
Disease: Ankylosing spondylitis
Ankylosing spondylitis 		0.330 Biomarker disease CTD_human Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. 21743469 2011
CUI: C0038013
Disease: Ankylosing spondylitis
Ankylosing spondylitis 		0.330 GeneticVariation disease BEFREE Here we report the identification of three variants in the RUNX3, LTBR-TNFRSF1A and IL12B regions convincingly associated with ankylosing spondylitis (P < 5 × 10(-8) in the combined discovery and replication datasets) and a further four loci at PTGER4, TBKBP1, ANTXR2 and CARD9 that show strong association across all our datasets (P < 5 × 10(-6) overall, with support in each of the three datasets studied). 21743469 2011
CUI: C0014175
Disease: Endometriosis
Endometriosis 		0.330 Biomarker disease CTD_human Results of the present study indicate that 1) PGE(2) promotes survival of human endometriotic cells through EP2 and EP4 receptors by activating ERK1/2, AKT, nuclear factor-kappaB, and beta-catenin signaling pathways; 2) selective inhibition of EP2 and EP4 suppresses these cell survival pathways and augments interactions between proapoptotic proteins (Bax and Bad) and antiapoptotic proteins (Bcl-2/Bcl-XL), facilitates the release of cytochrome c, and thus activates caspase-3/poly (ADP-ribose) polymerase-mediated intrinsic apoptotic pathways; and 3) these PGE(2) signaling components are more abundantly expressed in ectopic endometriosis tissues compared with eutopic endometrial tissues during the menstrual cycle in women. 19407222 2009
CUI: C0010093
Disease: Corpus Luteum Cyst
Corpus Luteum Cyst 		0.300 Biomarker disease CTD_human New insights into the pathogenesis of cystic follicles in cattle: microarray analysis of gene expression in granulosa cells. 21239663 2011
CUI: C0029927
Disease: Ovarian Cysts
Ovarian Cysts 		0.300 Biomarker disease CTD_human New insights into the pathogenesis of cystic follicles in cattle: microarray analysis of gene expression in granulosa cells. 21239663 2011
CUI: C0269102
Disease: Endometrioma
Endometrioma 		0.300 Biomarker disease CTD_human Selective inhibition of prostaglandin E2 receptors EP2 and EP4 induces apoptosis of human endometriotic cells through suppression of ERK1/2, AKT, NFkappaB, and beta-catenin pathways and activation of intrinsic apoptotic mechanisms. 19407222 2009
CUI: C0003865
Disease: Arthritis, Adjuvant-Induced
Arthritis, Adjuvant-Induced 		0.300 Biomarker disease CTD_human MF498 [N-{[4-(5,9-Diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-(2-methoxyphenyl)acetamide], a selective E prostanoid receptor 4 antagonist, relieves joint inflammation and pain in rodent models of rheumatoid and osteoarthritis. 18287210 2008
CUI: C0024299
Disease: Lymphoma
Lymphoma 		0.300 Therapeutic group CTD_human Prostaglandin E2 regulates B cell proliferation through a candidate tumor suppressor, Ptger4. 19075289 2008
CUI: C0237873
Disease: Physiological Sexual Disorders
Physiological Sexual Disorders 		0.300 Therapeutic phenotype CTD_human Identification of prostaglandin E2 receptors mediating perinatal masculinization of adult sex behavior and neuroanatomical correlates. 18726914 2008
CUI: C0971858
Disease: Arthritis, Collagen-Induced
Arthritis, Collagen-Induced 		0.300 Biomarker disease CTD_human MF498 [N-{[4-(5,9-Diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-(2-methoxyphenyl)acetamide], a selective E prostanoid receptor 4 antagonist, relieves joint inflammation and pain in rodent models of rheumatoid and osteoarthritis. 18287210 2008
CUI: C0993582
Disease: Arthritis, Experimental
Arthritis, Experimental 		0.300 Biomarker disease CTD_human MF498 [N-{[4-(5,9-Diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-(2-methoxyphenyl)acetamide], a selective E prostanoid receptor 4 antagonist, relieves joint inflammation and pain in rodent models of rheumatoid and osteoarthritis. 18287210 2008
CUI: C0263454
Disease: Chloracne
Chloracne 		0.300 Biomarker disease CTD_human Microarray analysis of gene expression in peripheral blood mononuclear cells from dioxin-exposed human subjects. 17101203 2007
CUI: C0007193
Disease: Cardiomyopathy, Dilated
Cardiomyopathy, Dilated 		0.210 Biomarker group BEFREE We have previously reported that mice lacking the EP4 receptor in the cardiomyocytes develop heart failure with a phenotype of dilated cardiomyopathy. 31229524 2019
CUI: C0007193
Disease: Cardiomyopathy, Dilated
Cardiomyopathy, Dilated 		0.210 Biomarker group MGD
CUI: C0010692
Disease: Cystitis
Cystitis 		0.200 Biomarker disease RGD Intravesical immune suppression by liposomal tacrolimus in cyclophosphamide-induced inflammatory cystitis. 20860016 2011
CUI: C3178766
Disease: Nociceptive Pain
Nociceptive Pain 		0.200 Biomarker phenotype RGD Role of prostaglandin E2 in the synthesis of the pro-inflammatory cytokine interleukin-6 in primary sensory neurons: an in vivo and in vitro study. 21371033 2011
CUI: C0020429
Disease: Hyperalgesia
Hyperalgesia 		0.200 Therapeutic phenotype RGD A novel antagonist of the prostaglandin E(2) EP(4) receptor inhibits Th1 differentiation and Th17 expansion and is orally active in arthritis models. 20423341 2010
CUI: C0007787
Disease: Transient Ischemic Attack
Transient Ischemic Attack 		0.200 Biomarker disease RGD Expression of prostaglandin E2 receptor subtypes, EP2 and EP4, in the rat hippocampus after cerebral ischemia and ischemic tolerance. 16437207 2006